Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $615
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Eli Lilly and raises the price target from $500 to $615.
August 08, 2023 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Eli Lilly and raises the price target from $500 to $615, indicating a positive outlook for the company.
The raised price target by Wells Fargo indicates a positive outlook for Eli Lilly. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100